Kamada Stock Discussion

$Kamada (KMDA.US)$   Recent Developments: 🚀🚀🚀🚀👀
• Financial Guidance for 2025: On January 8, 2025, Kamada affirmed its 2024 financial guidance, expecting revenues between $158 million and $162 million, and adjusted EBITDA between $32 million and $35 million. For 2025, the company forecasts revenues between $178 million and $182 million, and adjusted EBITDA between $38 million and $42 million, representing a 13% increase in revenues and a 19% increase in adjusted EBITDA based on the mid-point of ...

$Kamada (KMDA.US)$
Kamada Announces a $25 Million 3-Year Contract for Supply of KAMRAB® and VARIZIG® in Latin America
Kamada (NASDAQ: KMDA) has secured a significant $25 million contract for supplying KAMRAB® and VARIZIG® in Latin America over a three-year period from 2025-2027. This contract with an international organization reinforces Kamada's position in the specialty plasma-derived field.
KAMRAB is used for post-exposure prevention of rabies infection, while VARIZIG is indicated for pos...

$Kamada (KMDA.US)$ Reuters
1 min ago
Kamada Announces a $25 Million 3-Year Contract for Supply of Kamrab® and Varizig® in Latin America

$Kamada (KMDA.US)$ Kamada: FDA Agrees With Error Control Rate Change for Phase 3 Trial for Alpha-1 Antitrypsin >KMDA.TA.TV
Dow Jones· 4 mins ago

$Kamada (KMDA.US)$ Press Release: Kamada Reports Strong First Quarter 2024 Financial Results With Year-Over-Year Top-Line Growth of 23% and a 96% Increase in Profitability; Raises Full-Year Financial Guidance